Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“Small
Pharma”), a biotechnology company focused on short-duration
psychedelic-assisted therapies for mental health conditions and
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin”), a
clinical-stage biopharmaceutical company committed to
revolutionizing mental healthcare by developing new and innovative
psychedelic-based treatment options, are pleased to announce that
Small Pharma has obtained a final order of the Supreme Court of
British Columbia approving the previously announced plan of
arrangement (the “Plan of Arrangement”) under Division 5 of
Part 9 of the Business Corporations Act (British Columbia) (the
“Final Order”).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231017215015/en/
Pursuant to the terms of the Plan of Arrangement, and in
accordance with the terms of the arrangement agreement dated August
28, 2023 between Small Pharma and Cybin (the “Arrangement
Agreement”), Cybin has agreed to acquire all of the issued and
outstanding securities of Small Pharma in an all-share transaction
(the “Arrangement”).
It is currently anticipated that the effective date of the
Arrangement will occur on or about October 23, 2023 upon the
satisfaction or waiver of customary closing conditions as set forth
in the Arrangement Agreement, which include, among other things,
the receipt of final approval of the Arrangement from the TSX
Venture Exchange (the “TSXV”).
Upon completion of the Arrangement, it is expected that the
common shares in the capital of Small Pharma (the “Small Pharma
Shares”) will be delisted from the TSXV and removed from the
OTCQB Venture Market, and Small Pharma will cease to be a reporting
issuer in each of the provinces and territories in Canada.
Further details with respect to the Arrangement are included in
the management information circular of Small Pharma dated September
13, 2023, which can be found on Small Pharma’s profile on SEDAR+ at
www.sedarplus.ca, and the management information circular of Cybin
dated September 13, 2023, which can be found on Cybin’s profile on
SEDAR+ at www.sedarplus.ca and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov.
About Small Pharma
Small Pharma is a biotechnology company progressing a pipeline
of short-duration psychedelic-assisted therapies for the treatment
of mental health conditions. Small Pharma has a portfolio of
clinical-stage N,N-Dimethyltryptamine (“DMT”) based assets,
SPL026 and SPL028. The Company was granted an Innovation Passport
designation for SPL026 from the U.K. Medicines and Healthcare
products Regulatory Agency (the “MHRA”) and has a pipeline
of proprietary preclinical assets.
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission
to create safe and effective psychedelic-based therapeutics to
address the large unmet need for new and innovative treatment
options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported
by a network of world-class partners and internationally recognized
scientists aimed at progressing proprietary drug discovery
platforms, innovative drug delivery systems, and novel formulation
approaches and treatment regimens. Cybin is currently developing
CYB003, a proprietary deuterated psilocybin analog for the
treatment of major depressive disorder and CYB004, a proprietary
deuterated DMT molecule for generalized anxiety disorder and has a
research pipeline of investigational psychedelic-based
compounds.
Headquartered in Canada and founded in 2019, Cybin is
operational in Canada, the United States, the United Kingdom, the
Netherlands and Ireland. For company updates and to learn more
about Cybin, visit www.cybin.com or follow the team on X, LinkedIn,
YouTube and Instagram.
Cautionary Notes and Forward-Looking Statements
This press release contains statements that constitute
“forward-looking information” (“forward-looking
information”) within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking information and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that discusses predictions, expectations,
beliefs, plans, projections, objectives, assumptions, future events
or performance (often but not always using phrases such as
“expects”, or “does not expect”, “is expected”, “anticipates” or
“does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking information.
Forward-looking statements in this news release include
statements regarding: the Arrangement; the terms and conditions
pursuant to which the Arrangement will be completed, if at all; the
anticipated timing for, and receipt of necessary regulatory
approvals for the Arrangement; the completion of the Arrangement,
including the satisfaction or waiver of all closing conditions,
delisting of the Small Pharma Shares from the TSXV and removal from
the OTCQB Venture Market, Small Pharma ceasing to be a reporting
issuer, and the anticipated timing of such events. In disclosing
the forward-looking information contained in this press release,
Small Pharma and Cybin have made certain assumptions. Although
Small Pharma and Cybin believe that the expectations reflected in
such forward-looking information are reasonable, it can give no
assurance that the expectations of any forward-looking information
will prove to be correct. Known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking information.
Such factors include, but are not limited to: the ability of
Small Pharma and Cybin to obtain all necessary regulatory approvals
or satisfy conditions to the completion of the Arrangement; general
business, economic, competitive, political and social
uncertainties; and other factors discussed in each of Small
Pharma’s and Cybin’s public filings, which are available on their
respective profiles on SEDAR+ at www.sedarplus.ca. Accordingly,
readers should not place undue reliance on the forward-looking
information contained in this press release. Except as required by
law, Small Pharma and Cybin disclaim any intention and assumes no
obligation to update or revise any forward-looking information to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking information or otherwise.
Small Pharma makes no medical, treatment or health benefit
claims about its proposed products. The MHRA or other similar
regulatory authorities have not evaluated claims regarding
DMT-assisted therapies and other next generation psychoactive
compounds. The efficacy of such therapies has not been confirmed by
MHRA-approved research. There is no assurance that such
DMT-assisted therapies and other psychoactive compounds can
diagnose, treat, cure or prevent any disease or condition. Vigorous
scientific research and clinical trials are needed. Any references
to quality, consistency, efficacy and safety of potential therapies
do not imply that Small Pharma verified such in clinical trials or
that Small Pharma will complete such trials. If Small Pharma cannot
obtain the approvals or research necessary to commercialize its
business, it may have a material adverse effect on Small Pharma’s
performance and operations.
Cybin makes no medical, treatment or health benefit claims about
Cybin’s proposed products. The U.S. Food and Drug Administration,
Health Canada, the European Medicines Agency, the MHRA, or other
similar regulatory authorities have not evaluated claims regarding
psilocybin, psychedelic tryptamine, tryptamine derivatives or other
psychedelic compounds. The efficacy of such products has not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds can diagnose, treat, cure or prevent
any disease or condition. Rigorous scientific research and clinical
trials are needed. Cybin has not conducted clinical trials for the
use of its proposed products. Any references to quality,
consistency, efficacy and safety of potential products do not imply
that Cybin verified such in clinical trials or that Cybin will
complete such trials. If Cybin cannot obtain the approvals or
research necessary to commercialize its business, it may have a
material adverse effect on the performance and operations of
Cybin.
The TSXV has neither approved nor disapproved the contents of
this news release. Neither the TSXV nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this
release.
Neither the Cboe Canada, operating as the Neo Exchange Inc. nor
the NYSE American LLC stock exchange have approved or disapproved
the contents of this news release and are not responsible for the
adequacy and accuracy of the contents herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017215015/en/
Small Pharma Inc. George Tziras, Chief Executive Officer
Email: ir@smallpharma.co.uk Tel: +44 (0)7456 915 968
Cybin Investor & Media Contact: Gabriel Fahel Chief
Legal Officer Cybin Inc. 1-866-292-4601 irteam@cybin.com – or –
media@cybin.com
Small Pharma (TSXV:DMT)
過去 株価チャート
から 11 2024 まで 12 2024
Small Pharma (TSXV:DMT)
過去 株価チャート
から 12 2023 まで 12 2024
